--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...
Scientists at the Karolinska Institutet in Sweden have found a new region in the c-Myc oncogene that would allow the development of a binding compound to target it. Their discovery is based on a ...
There is increasing evidence that sustained oncogene expression may be required to maintain the cancer state, implying that therapeutic strategies that use transient pharmacological inactivation may ...
Cancer-associated genes called oncogenes are well known to stimulate cell growth and division — causing tumors to balloon and spread. But now, researchers at the Stanford School of Medicine and ...
UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals. The company is also exploring translational and commercial ...
TAIPEI and SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) ...
Could a natural check on cancer be used to stop the disease? It's possible, but to leverage a system that nature designed, we must first understand it. Researchers led by a team at Purdue University ...
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback